companiesCompany
Y-mAbs Therapeutics
MSK spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy.
Naxitamab (Danyelza, accelerated approval November 2020); omburtamab (B7-H3, 131I) rejected by FDA in 2022; SADA pretargeted radioimmunotherapy platform (GD2-SADA, 177Lu) in phase 1.